This HTML5 document contains 85 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n29http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01010/identifier/drugbank/
n11http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n17http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01010/identifier/national-drug-code-directory/
n5http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01010/identifier/chemspider/
n8http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB01010/identifier/chebi/
n13http://www.drugs.com/mtm/
n28http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01010/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/ontology/mesh/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01010/identifier/pharmgkb/
n3http://linked.opendata.cz/ontology/drugbank/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01010/identifier/pdb/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01010/identifier/kegg-compound/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB01010/identifier/pubchem-compound/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01010/identifier/pubchem-substance/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01010
rdf:type
n3:Drug
n3:description
A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. [PubChem]
n3:dosage
n5:271B50BB-363D-11E5-9242-09173F13E4C5 n5:271B50BC-363D-11E5-9242-09173F13E4C5 n5:271B50BA-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
Distribution half-life is 7 to 12 minutes. Elimination half-life is 33 to 110 minutes.
n3:indication
For the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises.
n3:manufacturer
n4:271B50B2-363D-11E5-9242-09173F13E4C5 n4:271B50B3-363D-11E5-9242-09173F13E4C5 n4:271B50B4-363D-11E5-9242-09173F13E4C5 n4:271B50B5-363D-11E5-9242-09173F13E4C5 n4:271B50B6-363D-11E5-9242-09173F13E4C5
owl:sameAs
n8:DB01010 n28:DB01010
dcterms:title
Edrophonium
adms:identifier
n15:Edrophonium n18:251408 n19:3090 n20:3202 n22:46507530 n23:EDR n24:PA449437 n25:C06976 n26:10019-873-15 n27:DB01010
n3:mechanismOfAction
Edrophonium works by prolonging the action acetylcholine, which is found naturally in the body. It does this by inhibiting the action of the enzyme acetylcholinesterase. Acetylcholine stimulates nicotinic and muscarinic receptors. When stimulated, these receptors have a range of effects.
n3:packager
n4:271B50AD-363D-11E5-9242-09173F13E4C5 n4:271B50AE-363D-11E5-9242-09173F13E4C5 n4:271B50B1-363D-11E5-9242-09173F13E4C5 n4:271B50AF-363D-11E5-9242-09173F13E4C5 n4:271B50B0-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Edrophonium is primarily renally excreted with 67% of the dose appearing in the urine. Hepatic metabolism and biliary excretion have also been demonstrated in animals
n3:synonym
N-ethyl-3-hydroxy-N,N-dimethylanilinium (3-Hydroxyphenyl)dimethylethylammonium Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium 3-hydroxy-N,N-dimethyl-N-ethylanilinium Edrophonium Ion EDR N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium Edrophonium
n3:toxicity
With drugs of this type, muscarine-like symptoms (nausea, vomiting, diarrhea, sweating, increased bronchial and salivary secretions and bradycardia) often appear with overdosage (cholinergic crisis).
n3:volumeOfDistribution
* 1.6±0.4 L/kg [Adults] * 2.2±1.5 L/kg [Children (0.08-10 yrs)] * 1.8±1.2 L/kg [Elderly (65-75 yrs)]
n10:hasAHFSCode
n11:36-56-00
n3:salt
n3:synthesisReference
Terrell, R.C.; U.S. Patents 3,469,011; September 23, 1969 and 3,527,813; September 8, 1970; both assigned to Air Reduction Company, Incorporated.
n16:hasConcept
n17:M0007057
foaf:page
n13:edrophonium.html n29:edrophonium.htm
n3:IUPAC-Name
n6:271B50C1-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B50C7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B50C6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B50C3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B50C4-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B50C5-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B50D7-363D-11E5-9242-09173F13E4C5 n6:271B50BF-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B50D9-363D-11E5-9242-09173F13E4C5 n6:271B50BD-363D-11E5-9242-09173F13E4C5 n6:271B50C0-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B50BE-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n6:271B50CD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B50CE-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B50C8-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B50C9-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B50CB-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B50CA-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B50CC-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed.
n3:affectedOrganism
Humans and other mammals
n3:category
n3:clearance
* 6.8 +/- 2. mL/kg/min [Adults] * 6.4 +/- 3.9 mL/kg/min [Children (0.08-10 yrs)] * 2.9 +/- 1.9 mL/kg/min [Elderly (65-75 yrs)]
n3:containedIn
n9:271B50B9-363D-11E5-9242-09173F13E4C5 n9:271B50B7-363D-11E5-9242-09173F13E4C5 n9:271B50B8-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B50D3-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B50D5-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B50D6-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B50D8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B50D2-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B50D1-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B50D4-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B50C2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B50CF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B50D0-363D-11E5-9242-09173F13E4C5